M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Summary

This phase Ib trial studies the best dose and side effects of eribulin mesylate when given together with M7824)in treating patients with triple negative breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as M7824, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving eribulin mesylate and M7824 may work better at treating triple negative breast cancer.

Timeline

Start

2018-05-30

Primary completion

2022-09-21

Completion

2022-09-21

Outcome

Outcome not reported

Stopped: “Due to the fact that the sponsor decided not to move forward with the development of M7824”

Drugs

Indications